Effect of Age on Substantia Nigra Hyper-echogenicity in Parkinson's Disease Patients and Healthy Controls.


Journal

Ultrasound in medicine & biology
ISSN: 1879-291X
Titre abrégé: Ultrasound Med Biol
Pays: England
ID NLM: 0410553

Informations de publication

Date de publication:
01 2019
Historique:
received: 15 06 2018
revised: 13 09 2018
accepted: 18 09 2018
pubmed: 30 11 2018
medline: 20 6 2019
entrez: 29 11 2018
Statut: ppublish

Résumé

Substantia nigra (SN) hyper-echogenicity (SN+) describes an enlargement (>90th percentile) of the area of echogenicity at the anatomic site of the SN in the midbrain detected by transcranial sonography. This ultrasound sign has proven to be a valuable marker supporting the clinical diagnosis of Parkinson's disease (PD). Although there is considerable variation in the extent of echogenic signals at the anatomic site of the SN among PD patients, previous work suggests that SN+ is a stable marker throughout the course of the disease. The present study focused on two aspects: (i) determining whether SN+ values differ between the sides, mirroring the asymmetric character of the disease; and (ii) determining whether age has an influence on SN echogenicity. This cross-sectional study included 300 PD patients and 200 healthy controls. SN+ was measured planimetrically by transcranial sonography. Echogenicity was analyzed separately for onset and non-onset sides, with onset side defined as the SN contralateral to the side of the body that first manifested PD-related motor impairment. Age of the patients and healthy controls at study time was used for correlation. We found that the onset SN+ contralateral to the side of initial motor symptoms was on average 17.6% larger than its counterpart. However, we also found that contrary to the control group, where an increase in age was associated with an increase in size of SN+, age of PD patients was associated with a decline in size of the onset SN+. Furthermore, SN measured at the onset side of PD patients correlated significantly with patient age and Hoehn and Yahr stage, a scale that grades PD severity, although this was not the case for the non-onset side. The present study indicates that changes in SN echogenicity have a different dynamic depending on the onset side of the disease. The age at study time had a significantly negative effect on the size of onset SN+, the effect on the non-onset side was non-significant. We conclude that for appropriate PD analysis, onset SN+ is a more important marker than the average of both sides of SN. Furthermore, we found that among healthy controls, the size of SN+ increases with age.

Identifiants

pubmed: 30482710
pii: S0301-5629(18)30418-6
doi: 10.1016/j.ultrasmedbio.2018.09.018
pii:
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

122-128

Informations de copyright

Copyright © 2018 Elsevier Ltd. All rights reserved.

Auteurs

Toomas Toomsoo (T)

Center of Neurology, East Tallinn Central Hospital, Tallinn, Estonia. Electronic address: toomas.toomsoo@itk.ee.

Inga Liepelt-Scarfone (I)

Department of Neurodegeneration, Center of Neurology, Hertie Institute of Clinical Brain Research and German Center of Neurodegenerative Diseases, University of Tübingen, Tübingen, Germany.

Daniela Berg (D)

Department of Neurodegeneration, Center of Neurology, Hertie Institute of Clinical Brain Research and German Center of Neurodegenerative Diseases, University of Tübingen, Tübingen, Germany; Department of Neurology, Christian-Albrechts-University of Kiel, Kiel, Germany.

Riina Kerner (R)

Statistics Estonia, Tallinn, Estonia.

Allan-Hermann Pool (AH)

Center of Neurology, East Tallinn Central Hospital, Tallinn, Estonia.

Liis Kadastik-Eerme (L)

Department of Neurology and Neurosurgery, University of Tartu, Tartu, Estonia.

Inna Rubanovits (I)

Center of Neurology, East Tallinn Central Hospital, Tallinn, Estonia.

Toomas Asser (T)

Department of Neurology and Neurosurgery, University of Tartu, Tartu, Estonia.

Pille Taba (P)

Department of Neurology and Neurosurgery, University of Tartu, Tartu, Estonia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH